Higher-Dose Anticoagulation Not a Sure Bet for Hospitalized COVID Patients

“Trials evaluating anticoagulation in patients hospitalized for COVID-19 did not consistently favor stepping up dosing for short-term survival, according to a systematic review and prospective meta-analysis…

However, how much better one dose of any anticoagulant is than another may now be a moot point.

‘Even if the results provided clear direction about the benefits of higher-dose anticoagulation for a particular patient subgroup, whether the results would be appropriately applied to the patients admitted with COVID-19 today is not assured,’ noted Claire Shappell, MD, MPH, of Brigham and Women’s Hospital in Boston, and George Anesi, MD, MSCE, MBE, of the University of Pennsylvania Perelman School of Medicine in Philadelphia.

In their accompanying editorial, they nevertheless commended the prospective nature of the meta-analysis design as it allowed for higher-quality data harmonization across a larger sample.”

Read more at MedPage Today.